Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ASLN 2.53,l2 looks great to break hard
ASLN~~Bukwang Pharmaceutical has entered into co-promotion agreement with Sanofi- Aventis Korea on Aprovel? product family
January 2, 2020
Bukwang Pharmaceutical announced that it has entered into an agreement with Sanofi-Aventis Korea to co-promote an ARB class antihypertensive drugs, Aprovel? (active ingredient: irbesartan) and Co-aprovel? (active ingredient: irbesartan + hydrochlorothiazide).
Starting from January 2020, Bukwang and Sanofi-Aventis Korea will co-promote to sell and market the products for hospitals and clinics nationwide. The annual sales of Aprovel? and Co-aprovel? were recorded over 20 billion KRW in 2018 based on UBIST data.
Aprovel?(ingredient: irbesartan) is an angiotensin II receptor blocker (ARB) class antihypertensive drug. Aprovel?showed clinical efficacy in both hypertension and diabetic nephropathy, so it is considered to be the most effective treatment in patients with type 2 diabetes and hypertension. In addition, the combination of the ARB with diuretic agent, Co-aprovel?(ingredient: irbesartan + hydrochlorothiazide) provides effective efficacy for patients who do not adequately controlled with monotherapy.
About 80% of Bukwang’s sales comes from original/branded products. The company has proven its ability to maintain and grow the sales of original/branded products even after generic introduction in the market. Bukwang expects overall revenue growth due to its recent activities in introducing new original products.
“Through the co-promotion of Aprovel with Sanofi-Aventis Korea, Bukwang aims to establish a solid footprint in circulatory/cardiovascular area and to achieve its goal to reach 200 billion KRW sales in 2020.”, Bukwang’s representative said.
ASLN~~Bukwang initiates dosing of JM-010 in Europe phase 2 study
January 10, 2020
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe.
In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010, which is being developed to treat dyskinesia in Parkinson’s disease, in a number of European countries, and the progress is cruising as company expected.
JM-010 is a new drug candidate developed by Bukwang’s subsidiary, Contera Pharma, Copenhagen based CNS focused bioventure, to treat dyskinesia in Parkinson’s disease patients. Dyskinesia is an inevitable symptom that occurs to ~90% of patients who take levodopa.
Currently, there is no treatment available in Europe, therefore not only investigators but also patients show strong interest in this clinical study.
Bukwang representative said, “Beginning with the first patient dosing, the company will speed up the clinical study by enrolling more patients, and eventually make LID treatment available to Parkinson’s patients.”
JM-010 phase 2 clinical study in Europe is cruising, and expecting to have results in 2021.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
Zacks
Zacks Equity Research
,Zacks•January 13, 2020
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
More
ASLAN Pharmaceuticals Ltd. (ASLN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for ASLAN Pharmaceuticals Ltd. basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For ASLAN Pharmaceuticals Ltd. rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
Earnings Estimate Revisions for ASLAN Pharmaceuticals Ltd.
For the fiscal year ending December 2019, this company is expected to earn -$0.67 per share, which is a change of 52.1% from the year-ago reported number.
Analysts have been steadily raising their estimates for ASLAN Pharmaceuticals Ltd. Over the past three months, the Zacks Consensus Estimate for the company has increased 26.6%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of ASLAN Pharmaceuticals Ltd. to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ASLAN Pharmaceuticals Ltd. (ASLN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Start the conversation
Mihail
Share your reaction
How are you feeling today?
BullishNeutralBearish
GuidelinesPost
Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?
Zacks
Zacks Equity Research
,Zacks•January 6, 2020
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ASLAN Pharmaceuticals (ASLN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ASLN and the rest of the Medical group's stocks.
ASLAN Pharmaceuticals is a member of our Medical group, which includes 909 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ASLN is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ASLN's full-year earnings has moved 26.61% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ASLN has gained about 6.40% so far this year. Meanwhile, the Medical sector has returned an average of -0.70% on a year-to-date basis. This shows that ASLAN Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, ASLN belongs to the Medical - Biomedical and Genetics industry, a group that includes 389 individual stocks and currently sits at #57 in the Zacks Industry Rank. On average, this group has lost an average of 1.44% so far this year, meaning that ASLN is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ASLN. The stock will be looking to continue its solid performance.
Click to get this free report ASLAN Pharmaceuticals Ltd. (ASLN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
ASLN~~chart is ready to break,news also due to hit the board,could see $8.00++ this month
* * $ASLN Video Chart 01-10-2020 * *
Link to Video - click here to watch the technical chart video
Exactly one month ago, ASLN was trading at $8. Let's get some of that back.
Load up.....I know the clueless IDIOTS selling it. And they know NOTHING as Cramer would say!!! Just idiots with tons of cash. Load.
ASLN ~ 2.05 and Lower ...
Y I K E S
I got Out last week @ 2.25 LOL Its on Piece Of Cheat status now!! Load up on HSDT all in from .95 $$$
Clueless idiots still shorting ASLN...LMFAOO. These guys are just Zombies. Losing all over the place and expecting a difference. Fools.
Explode it above 2.43 is all it needs then a huge explosion follows next!! $$$
Im Back All In from 2.35 See ya back @ 6.25 for the January Effect Boomage!!! $$$
Kept laughing my ass off at these fools here as they try to keep ml it at $2.20. I got some more today at $2.16....four min6i to start of trading
* * $ASLN Video Chart 12-18-2019 * *
Link to Video - click here to watch the technical chart video
LMFAOO...on these sellers. LESSON ONE: Alexander the Great recognized before Christ that NO ONE IS STRONG ENOUGH TO BE ALWAYS THE MASTER.
So, Get outta here, CLUELESS FOOLS
Lol...don't miss out on AIHS
..same shorts same thing, but likely will triple
Some buying coming in... close above 2,80 be geratene 3,50plus tomorrow
$3.50....taje bbn it or lose it! I'm done posting here. Let's turn to N other stocks we control. For a list, click on my name. Seems odd, but that's the 100 percent truth.
That shows how awfully stupid some of these people that trade heavy in this market could be. No BRAINS, except the trickery they use in convincing investors to give them money to mlm invest. I am flabbergasted!!!!
Yeah lol ;)
Let’s make some Profit here now... I just belive the gap has a lil to much gravity
Feeling infinitely powerful that I determine the price action of several stocks just by a comment on Ihub. Amazing how I achieved this...but like Trump will say, I guess I am smart. Lol. Just kidding
These guys selling this are pathetically idiotic in their cluelessness. They've made me tons of money. I have to patent them if I can. I wish!!!
No gap....I played the foolish shorts. Sold a couple of thousands at $2.86 while holding the rest. Then I n posted my first enjoy ride move. I knew they would react. So, now just bought back the stuff I sold at $2.86...at $2.48. The want the play...I have the arrows. LMFAOO again!
The gap is such a sucker... let’s sucker
smartass not looking good when you are here lol
Oh BOY...watch out. LMFAOO. $3.50 here we go!
I won’t make to many... going to Christkindl Markt having some Glühwein ;)
lets see how many posts the jackal makes today
lets count
smartass why you blocked PM,fear?
$3.50 target by Friday
see you smartass
prideass definetly change your profile name
got better name smartprideass
Looking strong
I don’t have 40k this time... but still quiet a few ;)
ASLN connection here ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
November 13, 2019
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseases including Alzheimer’s Disease, today announced the signing of a binding agreement for a $ US 3.6 million equity financing round. The financing was co-led by Bukwang Pharmaceutical, Fonds de solidarité FTQ, together with existing investors FutuRx, OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc. and RM Global Partners (RMGP) BioPharma Investment Fund. Proceeds from the financing will be used primarily to select a lead drug candidate molecule and validate its neurotherapeutic effects in vivo. In addition, the company plans to initiate the clinical development of a related diagnostic assay for patient selection and treatment personalization.
“We are happy to welcome new investors Fonds de solidarité Bukwang Pharmaceutical and FTQ, and greatly appreciate the continued support, guidance and assistance of our existing investors,” said Yotam Nisemblat, CEO of ProteKt Therapeutics. “The new funding will enable us to select and validate novel and selective neuroinflammation inhibitors and continue their development all the way to clinical studies with our next financing round. In addition, adopting a precision medicine approach and developing a patient selection diagnostic assay should increase the likelihood for an effective treatment”.
“We are proud to see our portfolio company ProteKt graduate from the FutuRx incubator with the capability to continue its development of novel therapies for unmet medical needs in neurology such as neurodegenerative diseases with the help of new and existing investors,” said Kinneret Savitzky, Ph.D., CEO of FutuRx.
“The Fonds de solidarité FTQ’s investment in ProteKt is our first in the field of neurodegenerative diseases such as Alzheimer’s. We are delighted that ProteKt’s innovative approach will be combined with Québec’s expertise in medicinal chemistry in the fight against this devasting illness,” said Didier Leconte, Vice-President for Investments, Life Sciences and Funds-of-Funds at the Fonds.
“We are impressed with ProteKt’s capability in drug discovery and are delighted to be part of this financing round to move this promising program toward a treatment for neurodegenerative diseases. Bukwang has a strong R&D heritage and this financing round participation further strengthens Bukwang’s portfolio and emphasizes our commitment in the development of novel drugs targets,” said Hee-Won Yoo, Ph.D., CEO of Bukwang Pharmaceutical.
About ProteKt Therapeutics
ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company was founded by Carmel, Haifa University Economic Corporation, and the Carmel Innovations Fund based on the research of Prof. Kobi Rosenblum of the Haifa University. ProteKt Therapeutics joined the FutuRx accelerator in 2015, where it has discovered and developed a series of novel and selective molecules by applying unique computational methods and validating the inhibitors in clinically relevant assays.
About the Fonds de solidarité FTQ
The Fonds de solidarité FTQ is a capital development fund that channels the savings of Quebecers into investments. With $15.6 billion in net assets as of May 31, 2019, the Fonds has helped create and protect 215,104 jobs. The Fonds has 3,126 partner companies and today has more than 700,000 shareholders-savers.
ASLN~~~ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
September 30, 2019
ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to $5million to form JAGUAHR THERAPEUTICS
ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR antagonists
– ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, and Bukwang Pharmaceutical (KRX:003000), a leading R&D focused Korean pharmaceutical company, today announced that they have established a new joint venture to develop preclinical aryl hydrocarbon receptor (AhR) antagonists from ASLAN’s early stage pipeline. The independent company, JAGUAHR Therapeutics, will focus on developing new immuno-oncology therapeutics for global markets targeting the AhR pathway and will be based in Singapore.
Under the terms of the agreement, ASLAN will transfer the global rights to all of the assets related to AhR technology, originally discovered and developed by ASLAN and its collaborator Dr Mark Graham, into JAGUAHR. Bukwang will invest US$5 million in JAGUAHR in two tranches to fund the development of the assets, identify a lead development compound and file an Investigational New Drug application.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The launch of JAGUAHR Therapeutics is an important step by ASLAN to realise the value of our early stage assets and advance the development of our AhR antagonist technology at a time when focus is shifting towards AhR antagonists as a hot new area in immuno-oncology. Bukwang has a strong track record of achievement in the pharma business and creating this spinout together allows both companies to quickly progress these exciting compounds and potentially provide novel clinical assets to enrich the ASLAN pipeline. We look forward to working with the Bukwang team as we focus on identifying JAGUAHR’s first drug candidate.”
Dr Hee-Won Yoo, Chief Executive Officer, Bukwang Pharmaceutical, added: ““We are impressed and delighted to partner with ASLAN to establish JAGUAHR Therapeutics. Bukwang has a strong heritage in R&D and this agreement is aligned to our strategy to strengthen our innovative development pipeline and broaden early access to promising technology for treating conditions with unmet needs. We are very excited as the AhR antagonists program further marks Bukwang’s formal participation in the immuno-oncology arena. We look forward to working together with ASLAN to progress these novel immuno-oncology compounds into clinical development in oncology.”
AhR is a druggable transcription factor that acts as a master regulator of the immune system. The enzymes IDO1, IDO2 and TDO are frequently overexpressed in numerous tumour types and convert tryptophan into kynurenine (KYN) in the tumour microenvironment. KYN is then actively transported into dendritic cells and effector T-cells that are mobilised to detect and kill tumour cells. KYN signalling via AhR in these cell types converts them into regulatory T-cells, suppressing the immune system and preventing it from attacking tumour cells. Research has demonstrated that the unique advantages of AhR antagonists include broadly inhibiting the signalling of all AhR ligands produced by any enzyme that metabolises tryptophan, and robust activation of the immune response to kill cancer cells.
ASLN WOW~~Partners ASLAN is in a joint venture with Bukwang to develop preclinical aryl hydrocarbon receptor (AhR) antagonists. Bukwang Pharmaceutical Co., Ltd. [KRX:003000] was established on 17 October 1960 and has continued to produce and commercialise excellent medications with the aim of improving global health for close to 60 years. Bukwang has a solid business that covers a wide spectrum of indications such as liver, metabolic, CNS and oncology disease. Bukwang’s proven record of its core business provides financial assurance that enables Bukwang to continue pushing into more innovative area of new drug R&D. To learn more about Bukwang, please visit https://www.bukwangpharm.com/
ASLN~~HUGEE~~Our Pipeline
Our portfolio is comprised of one monocloncal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology.
http://aslanpharma.com/pipeline/
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
612
|
Created
|
11/22/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |